Although we did not find any correlation between the lymphocyte CTLA-4 expression and NPC patient clinical outcome in our study, we did find that the OS, FFS, and D-FFS rates in the low tumor CTLA-4 expression group were significantly higher than those in the high tumor CTLA-4 expression group. The gene discussed is CTLA4; the disease is nasopharyngeal carcinoma.